basel

Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety

Fourth annual initiative supports World Diabetes Day 2025 with patient-led creativity and storytellingBASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes…

2 days ago

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally…

3 days ago

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

July 02, 2025 01:00 ET  | Source: BioVersys Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02,…

3 weeks ago

Hyundai Motor Group Announces Grand Prix Recipient and Exhibitions of the 6th VH AWARD

Hyundai Motor Group premieres five commissioned artworks of the 6th VH AWARD screening at HEK (House of Electronic Arts) during…

1 month ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

1 month ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

1 month ago

Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…

2 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

2 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

2 months ago

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…

2 months ago